The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy for young children with sickle cell disease. This approval may have a significant impact on children worldwide, particularly in developing countries where access to new treatments is often limited.
International Implications
About 70% of countries around the world have underdeveloped regulatory drug approval processes and rely on reviews conducted by agencies designated as WHO-Listed Authorities. The FDA is one of these authorities, and its approval of the gene therapy may pave the way for its adoption in other countries.
The FDA’s approval process is rigorous and involves multiple phases of clinical trials, which can take around eight years to complete and cost approximately $1 billion. Only about 13% of experimental drugs that enter clinical trials are ultimately approved by the FDA.
Changes at the FDA
Recent changes at the FDA, including staff cuts and the introduction of a new pilot program, have raised concerns about the agency’s ability to regulate drug safety effectively. The pilot program allows certain pharmaceutical companies to receive accelerated approval for their experimental drugs, which may not be intended to treat life-threatening conditions.
Some experts worry that this program may compromise the FDA’s ability to ensure the safety and effectiveness of new drugs, which could affect its standing as a WHO-Listed Authority. This, in turn, may impact the adoption of new treatments in developing countries.
Original reporting: KTBS 3 (Shreveport) — read the source article.
